Sofinnova combines its sector expertise with AWS’s AI and cloud services to help life sciences companies scale faster The collaboration expands Sofinnova’s proprietary AI platform, Sofia, including a new founder-facing version PARIS, France – June 10, 2026 – Sofinnova Partners (“Sofinnova”), a leading European life sciences venture capital firm based in Paris, London, and Milan, […]
ARE vaccines coming in from the cold? That’s the question this week after Eli Lilly splashed out almost $4 billion on three vaccine biotechs, two of which are in the early stage of clinical development. All are developing jabs for or related to infectious diseases. Why’s this a big deal? Because everyone knows that […]
Series A co-led by Abingworth, DaVita Venture Group, and F-Prime with participation from Curie.Bio, SymBiosis, and U.S. Renal Care Partnership with Alebund Pharmaceuticals to gain exclusive global development and commercial rights outside of Greater China for AP306, a differentiated pan phosphate transporter inhibitor, the only agent blocking the active transport of phosphate Advancing Phase 2b […]
PDUFA action date for Hansa Biopharma’s imlifidase BLA set for December 19, 2026 Hansa Biopharma announced that the Food and Drug Administration (FDA) has notified the company that the previously accepted Biologics License Application (BLA) for imlifidase has been assigned a Prescription Drug User Fee Act (PDUFA) action date of December 19, 2026. 📺Optimum TV […]
